Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
Authors' conclusion
In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.
Study context
- Population
- Women from SURMOUNT-1, −3 and −4 living with obesity or overweight without T2D, categorised as pre-, peri- or post-menopause
- Comparison
- Tirzepatide vs placebo, by reproductive stage
- Primary endpoint
- Body weight change by reproductive stage
- Follow-up
- End of study treatment
Methodological detailssubgroup analysis by reproductive stage, retrospective categorisation
- Subgroup analysis by reproductive stage
- Retrospective categorisation
Primary result
As reported in the abstract
Body weight reduction from baseline (SURMOUNT-1)
P < 0.001
Further findings
Waist circumference reduction, premenopause (SURMOUNT-1) · end of study treatment
P < 0.001
Waist circumference reduction, perimenopause (SURMOUNT-1) · end of study treatment
P < 0.001
Waist circumference reduction, postmenopause (SURMOUNT-1) · end of study treatment
P < 0.001
| Outcome | Tirzepatide | Placebo |
|---|---|---|
| Body weight reduction ≥5%, across reproductive stage subgroups (SURMOUNT-1) · end of study treatment | 97% to 98% | 29% to 33% |
| WHtR ≤ 0.49 (low central adiposity) among baseline BMI < 35 kg/m², across reproductive stage subgroups (SURMOUNT-1) · end of study treatment | 30% to 52% | — not stated in the abstract |
— not stated in the abstract
SURMOUNT-3 and −4
- Similar results observed in SURMOUNT-3 and −4
Original publication
Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →